Zoetis Inc. (ZTS) to Issue Quarterly Dividend of $0.53 on December 1st

Zoetis Inc. (NYSE:ZTS) announced a quarterly dividend on Thursday, October 8th. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share on Tuesday, December 1st. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Friday, October 30th.

Zoetis has raised its dividend payment by an average of 0.2% annually over the last three years and has raised its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Zoetis to earn $6.33 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 33.5%.

Zoetis Stock Up 2.3%

NYSE:ZTS opened at $74.77 on Friday. The company’s 50-day simple moving average is $73.92 and its 200-day simple moving average is $84.85. The stock has a market capitalization of $30.90 billion, a P/E ratio of 12.32, a P/E/G ratio of 1.70 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $148.30.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the firm earned $1.76 earnings per share. The company’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts anticipate that Zoetis will post 6.20 earnings per share for the current fiscal year.

Institutional Trading of Zoetis

Several hedge funds have recently made changes to their positions in ZTS. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis in the first quarter valued at approximately $28,000. Root Financial Partners LLC boosted its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Wellington Grp LLC grew its stake in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the last quarter. Global Assets Advisory LLC acquired a new stake in Zoetis in the first quarter worth $38,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the second quarter valued at $25,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.